EUVIMEDOpdag EUVIMED
Open access

Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials

Masoumeh Amin-Esmaeili iD, Mehdi Farokhnia iD, Ryoko Susukida, Lorenzo Leggio iD, Renee M Johnson, Rosa M Crum, Ramin Mojtabai iD

Addiction · 2024-05 · 119 (5) · 833-843

DOI: 10.1111/add.16409 ↗

At a glance

Journal article in Addiction, published online on 2024-01-10. Written by Masoumeh Amin-Esmaeili and 6 co-authors. Institution: Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Major MEDLINE topics: Central Nervous System Stimulants, Cocaine, Methamphetamine, Substance-Related Disorders. Cited 46 times so far (Crossref); 59 references. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, Intramural NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and aims Total abstinence has historically been the goal of treatment for substance use disorders; however, there is a growing recognition of the health benefits associated with reduced use as a harm reduction measure in stimulant use disorders treatment. We aimed to assess the validity of reduced stimulant use as an outcome measure in randomized controlled trials (RCTs) of pharmacological interventions for stimulant use disorder.

Design

We conducted a secondary analysis of a pooled dataset of 13 RCTs. Setting and participants Participants were individuals seeking treatment for cocaine or methamphetamine use disorders ( N = 2062) in a wide range of treatment facilities in the United States.

Measurements

We validated reduced stimulant use against a set of clinical indicators drawn from harmonized measurements, including severity of problems caused by drug use, comorbid depression, global severity of substance use and improvement, severity of drug‐seeking behavior, craving and high‐risk behaviors, all assessed at the end of the trial, as well as follow‐up urine toxicology. A series of mixed effect regression models was conducted to validate reduction in frequency of use against no reduction in use and abstinence.

Findings

More participants reduced frequency of primary drug use than achieved abstinence (18.0% vs. 14.2%, respectively). Reduced use was significantly associated with decreases in craving for the primary drug [60.1%, 95% confidence interval (CI) = 54.3%–64.7%], drug seeking behaviors (41.0%, 95% CI = 36.6%–45.7%), depression severity (39.9%, 95% CI = 30.9%–48.3%), as well as multiple measures of global improvement in psychosocial functioning and severity of drug‐related problems, albeit less strongly so than abstinence. Moreover, reduced use was associated with sustained clinical benefit at follow‐up, as confirmed by negative urine tests (adjusted odds ratio compared with those with no reduction in use: 0.50, 95% CI = 0.35–0.71).

Conclusion

Reduced frequency of stimulant use appears to be associated with meaningful improvement in various clinical indicators of recovery. Assessment of reduced use, in addition to abstinence, could broaden the scope of outcomes measured in randomized controlled trials of stimulant use disorders and facilitate the development of more diverse treatment approaches.

Subjects

MeSH terms (MEDLINE)

Central Nervous System StimulantsCocaineMethamphetamineSubstance-Related DisordersHumansRandomized Controlled Trials as TopicMulticenter Studies as Topic

Author keywords

Stimulantscocaine use disorderharm reductionmethamphetamine use disordernon‐abstinence outcomessecondary data analysis

Substances

Central Nervous System StimulantsCocaineMethamphetamine

Authors and institutions

  • Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
  • Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran.
  • Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Al…
  • Medication Development Program, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
  • Center for Alcohol and Addiction Studies, Department of Behavioral and Social Sciences, Brown University, Providence, RI, USA.
  • Division of Addiction Medicine, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.

ORCID profiles: Masoumeh Amin-Esmaeili, Mehdi Farokhnia, Lorenzo Leggio, Ramin Mojtabai

Funding

  • NIDA NIH HHS
  • Intramural NIH HHS
  • National Institutes of Health
  • Intramural Research Program

Cite

APA

Amin-Esmaeili, M., Farokhnia, M., Susukida, R., Leggio, L., Johnson, R. M., Crum, R. M., & Mojtabai, R. (2024). Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction, 119(5), 833-843. https://doi.org/10.1111/add.16409

Vancouver

Amin-Esmaeili M, Farokhnia M, Susukida R, Leggio L, Johnson RM, Crum RM, et al. Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction. 2024;119(5):833-843. doi:10.1111/add.16409

BibTeX
@article{AminEsmaeili2024,
  author = {Amin-Esmaeili, Masoumeh and Farokhnia, Mehdi and Susukida, Ryoko and Leggio, Lorenzo and Johnson, Renee M and Crum, Rosa M and Mojtabai, Ramin},
  title = {Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials},
  journal = {Addiction},
  year = {2024},
  volume = {119},
  number = {5},
  pages = {833--843},
  doi = {10.1111/add.16409}
}
Start for free →